IMRTSIB and Concurrent CT for LAHNC: Toxicity and Quality of Life

Abstract

Objective: Evaluate the acute toxicity of postoperative radiotherapy with intensity modulated simultaneous integrated boost (IMRT-SIB) and the impact of this treatment on quality of life for patients with head and neck cancer locally advanced (LAHNC). Method(s): A total of 21 patients with histologically confirmed LAHNC received, from July 2008 to August 2010, postoperative IMRT-SIB and concurrent Cisplatin 100mg/m2 every 3 weeks. Quality of life was evaluated in 13 patients with M.D. Anderson Dysphagia Inventory, Karnofsky Performance Status, Performance Status Scale for Head & Neck Cancer, and EORTC H&N35. Result(s): Median follow-up was 10 months (range, 2-30 months). Acute mucositis >= G2 occurred in 18 patients. Acute reactions >= G2 on salivary glands in 15 patients. Acute reaction >= G3 appeared in 4 patients on mucosae and in 5 on pharynx. At time of analysis 18 patients were free from locoregional recurrence. Conclusion(s): IMRT-SIB and concurrent cisplatin is feasible and well tolerated in LAHNC and is not correlated with a decrease in healthy functioning, global health status, or subjective evaluation of level of illness.